Regeneron Pharmaceuticals Inc. (REGN)

627.25
4.80 0.77
NASDAQ : Health Technology
Prev Close 622.45
Open 635.00
Day Low/High 623.50 / 639.00
52 Wk Low/High 271.37 / 646.33
Volume 1.04M
Avg Volume 1.36M
Exchange NASDAQ
Shares Outstanding 110.67M
Market Cap 70.04B
EPS 19.40
P/E Ratio 31.28
Div & Yield N.A. (N.A)
I Wouldn't Buy Pfizer Shares on This Pop

I Wouldn't Buy Pfizer Shares on This Pop

I would wait until the next down day, and there will be one.

Regeneron Pharmaceuticals Has Made a Major Upside Breakout

Regeneron Pharmaceuticals Has Made a Major Upside Breakout

Now that REGN has clearly broken out above the highs of 2015 there is no chart resistance.

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?

Jim Cramer: 20 Stocks That Are Emblematic of What's Driving the Market

Jim Cramer: 20 Stocks That Are Emblematic of What's Driving the Market

This list is not a buy list but a list of stocks that have been brought to new heights.

Jim Cramer: Is the Day Where the Virus Ruled Our Lives Waning?

Jim Cramer: Is the Day Where the Virus Ruled Our Lives Waning?

That's the really good news about why we could bounce back so quickly from Thursday's debacle.

Risky Business, Painful Recovery, Trading Thoughts

Risky Business, Painful Recovery, Trading Thoughts

The massive tock market drop was to be expected, and seasoned traders were prepared for it. But there was also some good news on the coronavirus vaccine/treatment front.

Jim Cramer: What's Normalcy in This Country?

Jim Cramer: What's Normalcy in This Country?

We're cheering what may be an aberration, a bullish employment number. We'll take what it brings - a wholesale shift in what we're buying and what we're selling to fund it.

Regeneron, PayPal, Facebook Push Up Real Money Post Industrial Average

Regeneron, PayPal, Facebook Push Up Real Money Post Industrial Average

The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.

Jim Cramer: It's Still Better to Be Safe Than Sorry

Jim Cramer: It's Still Better to Be Safe Than Sorry

Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.

Jim Cramer: The Hope Is Real

Jim Cramer: The Hope Is Real

I get this rally -- it's based on more than a breaking branch this time, but there are still many uncertainties.

Regeneron Pharmaceuticals Could Trade Sideways Before Renewed Gains

Regeneron Pharmaceuticals Could Trade Sideways Before Renewed Gains

Use available weakness to go long or add to longs.

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.

Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room

Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room

Don't just follow the herd, time your exits and entrances well -- even if it is a big player like Warren Buffett that is leading the charge.

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.

Real Money Post-Industrial Average Feels the Pain, But Continues to Outperform

Real Money Post-Industrial Average Feels the Pain, But Continues to Outperform

For March and the first quarter, the RMPIA takes less of a hit than major indexes.

Jim Cramer: Here Are the Quarter's Winners, Losers

Jim Cramer: Here Are the Quarter's Winners, Losers

The five best performing and worst performing stocks in the S&P 500 in the previous quarter pretty much tells the tale of the tape, so here goes.

Jim Cramer: Here's the Science Behind Our Rally

Jim Cramer: Here's the Science Behind Our Rally

While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.

Sanofi's Charts Show Upside Potential Amid Its Covid-19 Work

Sanofi's Charts Show Upside Potential Amid Its Covid-19 Work

The drug and vaccine maker possibly could see its shares double according to a key chart.

Jim Cramer: The Rescue Bill and a Fed Dive-Bombing Policy Ignited All Sectors

Jim Cramer: The Rescue Bill and a Fed Dive-Bombing Policy Ignited All Sectors

I think our scientists, our medical minds, are working on an atomic bomb that can nuke Covid before it invades us.

Failed Rallies, Semiconductors Rising and the Fed's Big Guns

Failed Rallies, Semiconductors Rising and the Fed's Big Guns

The Fed has attacked developing problems in real-time -- and as China shows signs of life, the semi stocks are benefitting.

The Fed's Big Bazooka, Covid-19 Treatments, Market Breather

The Fed's Big Bazooka, Covid-19 Treatments, Market Breather

Amid dramatically rising jobless claims, the Fed continues to fire big bullets, the Senate is pushing its economic support package and Gilead and Regeneron have made progress on coronavirus treatments.

These Are the Times We Live In

These Are the Times We Live In

Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.

Regeneron Pharmaceuticals Could Be a Bright Spot in a Sea of Declines

Regeneron Pharmaceuticals Could Be a Bright Spot in a Sea of Declines

We looked at the charts of REGN yesterday but with things (read: stock prices) changing so fast it wouldn't hurt to look again.

The Magic Mice of Regeneron

The Magic Mice of Regeneron

I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.

Regeneron Pharmaceuticals Presents Bullish Charts Amid Covid-19 Work

Regeneron Pharmaceuticals Presents Bullish Charts Amid Covid-19 Work

The biopharma giant's work on a coronavirus antibody treatment is helping move its shares in a different direction than the market has taken.

5 Leading Biotechs in Search of a Coronavirus Vaccine

5 Leading Biotechs in Search of a Coronavirus Vaccine

The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.

This Stock Is Standing Up to the Correction Like Few Others

This Stock Is Standing Up to the Correction Like Few Others

Biotech name has bolted higher with some amazing relative strength.

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Regeneron's Pullback Amid Market Weakness Could Lead to Buying Opportunity

Regeneron's Pullback Amid Market Weakness Could Lead to Buying Opportunity

The biopharma giant could fall further, so wait for a candlestick reversal pattern before going long.